Stocks Health care RGC
NASDAQ · Health careRegencell Bioscience Holdings Ltd (RGC)
It posted a net loss of $3.6M. In fiscal 2025 capital spending exceeded operating cash flow by $3.3M. At June 30, 2025 it held $2.4M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on October 31, 2025.
What Regencell Bioscience Holdings Ltd does
Regencell Bioscience Holdings Ltd is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NASDAQ under the ticker RGC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$3.6M | -$0.72 | -$3.3M |
| 2024 | n/a | -$4.3M | -$0.87 | -$4M |
| 2023 | n/a | -$5.9M | -$1.19 | -$5M |
| 2022 | n/a | -$7.4M | -$1.53 | -$6M |
| 2021 | n/a | -$1.3M | -$0.34 | n/a |
| 2021 | n/a | -$812.4K | -$0.21 | -$844.4K |
Latest SEC filings
What Regencell Bioscience Holdings Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- May 22, 2026
- May 19, 2026
- May 19, 2026
- May 19, 2026
- May 8, 2026
- April 17, 2026
- March 30, 2026
- March 30, 2026
- March 30, 2026
- March 30, 2026Form F-3ASR filing F-3ASR
Questions about RGC
What does Regencell Bioscience Holdings Ltd do?
Regencell Bioscience Holdings Ltd is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NASDAQ under the ticker RGC.
Is Regencell Bioscience Holdings Ltd profitable?
No. In fiscal 2025 it reported a net loss of $3.6M.
When did Regencell Bioscience Holdings Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on October 31, 2025. It covers the period to June 30, 2025. Its newest filing of any kind is the insider trade from May 29, 2026.
Similar companies
Follow RGC
Get an email when Regencell Bioscience Holdings Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow RGC: get an email when it filesWhere the numbers come from
Financial figures are the values Regencell Bioscience Holdings Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.